Exhibit 99.1

FOR IMMEDIATE RELEASE
Contact:
Richard Baron		Brett Maas
eResearchTechnology, Inc.		Hayden Communications
215-282-5566		646-536-7331

eResearchTechnology Reports First Quarter 2007 Results

Reports Revenue of $21.1 Million, Earnings per Share of $0.04, and New Bookings of Nearly $30 million

PHILADELPHIA, PA May 3, 2007 /PRNewswire-FirstCall/ — eResearchTechnology, Inc. (NASDAQ: ERES — News; “eRT” or “the Company”), a leading provider of centralized ECG and eClinical technology and services to the pharmaceutical, biotechnology, medical device and related industries, announced today results for the quarter ended March 31, 2007.

The Company reported revenues of $21.1 million for the first quarter of 2007, an increase of 5.8% sequentially from the prior quarter’s revenue of $19.9 million. This compares to $21.4 million in revenue reported for the first quarter of 2006. In both the first quarter of 2007 and the fourth quarter of 2006, eRT reported net income of $2.2 million and $0.04 per diluted share . This compares to net income of $1.9 million, or $0.04 per diluted share, reported for the first quarter of 2006. On an after-tax basis, excluding expenses associated with the efficiency improvements announced in February 2007, the Company’s net income and earnings per diluted share would have been $2.7 million and $0.05, respectively. After adjusting the first quarter of 2006 for contract dispute settlement expense and management transition costs, the Company’s net income and earnings per diluted share would have been $2.6 million and $0.05, respectively. The operating margin in the first quarter of 2007 was 14.7% (17.9% excluding the efficiency improvement expenses). This compares to 15.8% in the fourth quarter of 2006 and 13.2% (18.4% excluding settlement and management transition charges) for the first quarter of 2006. The Company’s tax rate for the first quarter of 2007 was 38.4% compared to 40.1% in the first quarter of 2006.

eRT ended the quarter with $62.5 million in cash, cash equivalents and investments, an increase of $4.7 million from $57.8 million at the end of the fourth quarter of 2006 predominately due to net cash provided by operations.

“The industry is benefiting from an increasing focus on Thorough ECG trials and eClinical, as well as the trend toward more centralized collection of digital ECGs in routine trials. This stems from the continued high emphasis on cardiac safety in the industry. eRT is seeing this increased focus benefit our pipeline of new business,” commented Dr Michael McKelvey, President and CEO of eRT. “We remain positive on the outlook for the outsourcing of clinical trials as evidenced by improved growth rates throughout the CRO industry. We believe we are well-positioned to take advantage of these positive industry trends due to our strong ongoing relationships with pharmaceutical and biotechnology sponsors and our key strategic partners, such as CROs and clinical pharmacology units.”

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2007 financial guidance, involve a number of risks and uncertainties such as the Company’s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company’s financial results can be found in the Company’s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

eResearchTechnology, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)

		Three Months Ended March 31,
		2006				2007
Net revenues:
Licenses		$	638			$	782
Services			14,725				13,968
Site support			6,036				6,334
Total net revenues			21,399				21,084
Costs of revenues:
Cost of licenses			76				66
Cost of services			6,156				6,790
Cost of site support			4,153				4,195
Total costs of revenues			10,385				11,051
Gross margin			11,014				10,033
Operating expenses:
Selling and marketing			3,038				2,538
General and administrative			3,839				3,469
Research and development			1,314				925
Total operating expenses			8,191				6,932
Operating income			2,823				3,101
Other income, net			390				550
Income before income taxes			3,213				3,651
Income tax provision			1,289				1,403
Net income		$	1,924			$	2,248
Basic net income per share		$	0.04			$	0.04
Diluted net income per share		$	0.04			$	0.04
Shares used to calculate basic net income per share			49,102				50,198
Shares used to calculate diluted net income per share			51,685				51,431

eResearchTechnology, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share and per share amounts)

		December 31, 2006				March 31, 2007
						(unaudited)
ASSETS
Current assets:
Cash and cash equivalents		$	15,497			$	18,345
Short-term investments			41,416				43,203
Accounts receivable, net			17,866				16,217
Prepaid income taxes			2,819				1,499
Prepaid expenses and other			2,761				3,439
Deferred income taxes			912				912
Total current assets			81,271				83,615
Property and equipment, net			31,129				33,649
Goodwill			1,212				1,212
Long-term investments			928				932
Other assets			524				530
Total assets		$	115,064			$	119,938
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	4,360			$	2,153
Accrued expenses			3,445				3,528
Income taxes payable			781				781
Current portion of capital lease obligations			40				2,831
Deferred revenues			11,325				10,931
Total current liabilities			19,951				20,224
Capital lease obligations, excluding current portion			—				778
Deferred tax liabilities			1,491				1,574
Total liabilities			21,442				22,576
Stockholders’ equity:
Preferred stock-$10.00 par value, 500,000 shares authorized, none issued and outstanding			—				—
Common stock-$.01 par value, 175,000,000 shares authorized, 58,356,546 and 58,576,225 shares issued, respectively			584				586
Additional paid-in capital			83,493				84,962
Accumulated other comprehensive income			1,510				1,531
Retained earnings			70,225				72,473
Treasury stock, 8,247,119 shares at cost			(62,190	)			(62,190	)
Total stockholders’ equity			93,622				97,362
Total liabilities and stockholders’ equity		$	115,064			$	119,938

eResearchTechnology, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

		Three Months Ended March 31,
		2006				2007
Operating activities:
Net income		$	1,924			$	2,248
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			2,819				3,215
Cost of sale of equipment			420				383
Non-cash share-based compensation			730				483
Changes in operating assets and liabilities:
Accounts receivable			301				1,654
Prepaid expenses and other			(1,171	)			(681	)
Accounts payable			607				(2,209	)
Accrued expenses			(1,030	)			84
Income taxes			(2,070	)			1,395
Deferred revenues			(2,135	)			(398	)
Net cash provided by operating activities			395				6,174
Investing activities:
Purchases of property and equipment			(4,923	)			(2,490	)
Purchases of investments			(7,436	)			(26,633	)
Proceeds from sales of investments			4,266				24,842
Net cash used in investing activities			(8,093	)			(4,281	)
Financing activities:
Repayment of capital lease obligations			(37	)			(40	)
Proceeds from exercise of stock options			1,099				879
Stock option income tax benefit			1,493				109
Repurchase of common stock for treasury			(5,803	)			—
Net cash (used in) provided by financing activities			(3,248	)			948
Effect of exchange rate changes on cash			32				7
Net (decrease) increase in cash and cash equivalents			(10,914	)			2,848
Cash and cash equivalents, beginning of period			18,432				15,497
Cash and cash equivalents, end of period		$	7,518			$	18,345

eResearch Technology, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP Information
For the Three Months Ended March 31, 2006 and 2007
(in thousands)
(unaudited)

		2006				2007
Gross margin:
GAAP gross margin		$	11,014			$	10,033
			—				—
Non-GAAP income gross margin		$	11,014			$	10,033
Reconciliation of GAAP to Non-GAAP operating income:
GAAP operating income		$	2,823			$	3,101
Cost of efficiency improvements			—				676
CEO and CFO transition			469				—
Settlement of contract dispute			646				—
Subtotal of reconciling items			1,115				676
Non-GAAP operating income		$	3,938			$	3,777
Reconciliation of GAAP to Non-GAAP net income and net income per diluted share:
GAAP net income		$	1,924			$	2,248
Cost of efficiency improvements			—				416
CEO and CFO transition			281				—
Settlement of contract dispute			390				—
Subtotal of reconciling items			671				416
Non-GAAP net income		$	2,595			$	2,664
GAAP net income per diluted share		$	0.04			$	0.04
Non-GAAP net income per diluted share		$	0.05			$	0.05